Approximately 30,000–40,000 people die from liver disease each year, according to the American Liver Foundation.
“Although the artificial liver is not yet cleared for use on humans, these findings show promise as an effective treatment option for diseases like liver cancer and hepatitis, which is becoming an increasingly common diagnosis.”
For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant.
Developed by Scott Nyberg, M.D., Ph.D., principal investigator in the Artificial Liver and Liver Transplantation Laboratory at Mayo Clinic and liver transplant surgeon, the device uses healthy hepatocytes, or liver cells, from pigs to do the job of a normal, healthy liver, which aids in digestion and the removal of waste and toxins from the bloodstream. Treatment with the Spheroid Reservoir Bioartificial Liver (SRBAL) has been shown to reduce the severity of liver disease and improve survival in pigs. Future clinical studies are planned to assess the SRBAL as a less-invasive, long-term treatment option to liver transplantation. Results from a study using the device in a pivotal preclinical trial were published today in the Journal of Hepatology.
“Acute liver failure claims the lives of over 30 percent of people who are diagnosed with this condition. Liver transplantation has been the go-to option for treating acute liver failure, but it also comes with many risks and isn’t always an option, due to compatibility and availability of donor livers,” says Dr. Nyberg. “A bioartificial liver device could allow physicians to treat and extend the lives of more patients, safely and cost-effectively, with fewer risks.”
The study conducted by Dr. Nyberg was designed to serve as a preclinical trial on pigs with drug-induced acute liver failure. The animals were treated using the Spheroid Reservoir Bioartificial Liver and were injected with healthy donor hepatocytes to determine if this treatment method could reverse the severity of their disease.
“This study demonstrated that animals treated using the bioartificial liver responded to the healthy hepatocytes and reached the study endpoint with less disease severity than animals that received other forms of treatment,” said Dr. Nyberg. “Although the artificial liver is not yet cleared for use on humans, these findings show promise as an effective treatment option for diseases like liver cancer and hepatitis, which is becoming an increasingly common diagnosis.”
The Latest on: Bioartificial Liver
via Google News
The Latest on: Bioartificial Liver
- Acute Liver Failure in Neonates, Infants and Childrenon October 8, 2020 at 5:00 pm
Consequently, increasing interest has centered on the possibility of providing temporary liver support based on extracorporeal devices (artificial and bioartificial) or on hepatocyte ...
- Acute Liver Failure in Neonates, Infants and Childrenon October 7, 2020 at 5:01 pm
The mainstay of medical care is to minimize ALF complications and to limit additional morbidity.  One key to managing patients with ALF is avoidance of administering drugs that have no proven ...
- PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDAon October 2, 2020 at 6:39 am
When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted ...
- PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDAon October 2, 2020 at 6:31 am
When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy ...
- Institute of Liver and Biliary Sciences, IIT Delhi collaborate to resolve challenges in medical practice, health serviceson September 28, 2020 at 9:25 pm
IITD Collaborative Platform is to help in critical identification of the problems faced by the practicing doctors in metabolic and liver diseases, ranging from the ...
- IIT Delhi & ILBS Sign MoU To Solve Challenges In Medical Practice And Health Serviceson September 27, 2020 at 4:52 am
Delhi and Institute of Liver and Biliary Sciences (ILBS) Delhi have signed an MoU called ‘ILBS-IITD Collaborative Platform’. The agreement provides a platform to various collaborations that involve ...
- IIT Delhi, ILBS sign MoU to solve unmet challenges in medical practice and health serviceson September 26, 2020 at 11:06 am
Delhi and Institute of Liver and Biliary Sciences (ILBS), Delhi have signed an MoU to establish ‘ILBS-IITD Collaborative Platform’ initiating ...
- IIT Delhi And ILBS Tie Up To Solve Challenges In Medical Practice And Health Serviceson September 26, 2020 at 9:52 am
bio-sensor development; computational biology and big data; material sciences, liver dialysis membranes and machines and 3D bio-printing and bio-artificial liver.
- PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Periodon September 23, 2020 at 6:00 am
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, ...
via Bing News